FDA consultation on Potency Assurance for Cellular and GeneTherapy Products (Catapult’s regulatory round-up – february 2024)
| 4. | Potency Assurance for Cellular and GeneTherapy Products | End date 27th March 2024 | Draft guidance |
Published on the 5th of March 2024 in Catapult’s regulatory round-up for february 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (5 novembre 2024). FDA consultation on Potency Assurance for Cellular and GeneTherapy Products (Catapult’s regulatory round-up – february 2024). ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/12min





